$AMRN News

JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript

Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum

Amarin Q2 Earnings Call Highlights

Amarin Posts Surprise Q2 Profit on Cost Discipline, Shares Rise Pre-Market (NASDAQ:AMRN)

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming

Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Generic drugmakers gain key victory in ‘skinny label’ patent case

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin

Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN)

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia